Term
| hair loss associated with fibrosis and scar tissue that replaces and often permanently destroys the hair follicle |
|
Definition
|
|
Term
| hair loss without permanent destruction of the hair follicle |
|
Definition
|
|
Term
| most common type of hair loss, affecting approx. 30-40% of adult men and women |
|
Definition
|
|
Term
| most common cause of diffuse hair loss throughout scalp; reversible difficuse loss of mature, terminal hairs, usually following a significant stressful events |
|
Definition
|
|
Term
| usually more acute in onset, does not follow a classic distribution and is associated with hair loss on other body sites |
|
Definition
|
|
Term
| growth phase-- lasts two to three years |
|
Definition
|
|
Term
| involutional phase-- lasts two to three weeks |
|
Definition
|
|
Term
| resting phase-- lasts three to four months, hair is released from the hair shaft and shed at the end of telogen, the next cycle is initiated |
|
Definition
|
|
Term
| promotes hair growth by increasing the duration of anagen and enlarging miniaturized and suboptimal follicles |
|
Definition
|
|
Term
| 5 alpha reductase inhibitor |
|
Definition
|
|
Term
| may decline by as much has 50% in men taking even the 1 mg dos of finasteride |
|
Definition
| serum prostate specific antigen (PSA) |
|
|
Term
| enanthate and cypionate esters of testosterone; lipophilic leading to sustained release from muscle depots |
|
Definition
| Intramuscular Testosterone |
|
|
Term
| testosterone treatment of elderly men, especially with long-acting testosterone esters causes: |
|
Definition
|
|
Term
| relax the smooth muscle of prostate and provide a larger urethral opening (address dynamic component) |
|
Definition
|
|
Term
| shrink the prostate gland (address the structural component) |
|
Definition
| 5-alpha reductase inhibitors |
|
|
Term
| 1st dose phenomenon: many people will experience marked orthostatic hypotension upon the first dose |
|
Definition
| non-selective alpha blockers |
|
|
Term
|
Definition
|
|
Term
| inhibits enzyme phosphodiesterase 5, allowing cyclic GMP to accumulate within penis |
|
Definition
| Sildenafil, Vardenafil, Tadalafil |
|
|
Term
| only phosphodiesterase inhibiter that has visual side effects |
|
Definition
|
|
Term
| PDE5 inhibitor contraindications |
|
Definition
| nitrates; children or women; patients with known hypersensitivities |
|
|
Term
| SEs include HA, facial flushing, dizziness, rhinitis, upset stomach, temporary vision changes; muscle aches, prolonged erections |
|
Definition
|
|
Term
| causes blue vision in about 3% of men |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| alprastadil (caverject and edex) |
|
|
Term
|
Definition
|
|
